Context Therapeutics Inc stock is traded at $0.1958, with a volume of 451,543. It is up +4.20% in the last 24 hours and down -39.15% over the past month. Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Previous Close:
$0.1879
Open:
$0.1918
24h Volume:
451,543
Relative Volume:
0.23
Market Cap:
$17.99M
Revenue:
-
Net Income/Loss:
-$40.23M
P/E Ratio:
-
EPS:
-$0.4275
Net Cash Flow:
-$34.82M
1W Performance:
+3.54%
1M Performance:
-39.15%
6M Performance:
-91.88%
1Y Performance:
-81.70%
1-Day Range:
$0.18$0.1989
1-Week Range:
$0.18$0.2129
52-Week Range:
$0.18$3.62
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
267-225-7416Address
2001 MARKET STREET, PHILADELPHIA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS